CLN — Celon Pharma SA Income Statement
0.000.00%
Last trade - 00:00
- PLN754.62m
- PLN669.28m
- PLN194.59m
- 69
- 16
- 61
- 44
2018 December 31st | 2019 December 31st | R2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | PAS | PAS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 125 | 102 | 160 | 199 | 195 |
Cost of Revenue | |||||
Gross Profit | 97.1 | 78.9 | 123 | 137 | 128 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 89.6 | 95.3 | 164 | 210 | 232 |
Operating Profit | 35.6 | 6.9 | -3.67 | -10.5 | -37.3 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 37.5 | 7.81 | -5.59 | -15.1 | -36.4 |
Provision for Income Taxes | |||||
Net Income After Taxes | 29.7 | 11.9 | -0.917 | -11.6 | -39.3 |
Net Income Before Extraordinary Items | |||||
Net Income | 29.7 | 11.9 | -0.917 | -11.6 | -39.3 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 29.7 | 11.9 | -0.917 | -11.6 | -39.3 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.655 | 0.255 | -0.027 | -0.251 | -0.772 |
Dividends per Share |